<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059913</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-818</org_study_id>
    <nct_id>NCT04059913</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center study in dialysis CKD subjects to evaluate the&#xD;
      efficacy and relative safety of different dosing regimens of roxadustat over a 36-week&#xD;
      treatment period.&#xD;
&#xD;
      There are three study periods:&#xD;
&#xD;
        -  Screening Period (up to 4 weeks)&#xD;
&#xD;
        -  Treatment Period (36 weeks)&#xD;
&#xD;
      Part 1: Correction/Conversion Period (weeks 1-20)&#xD;
&#xD;
      Part 2: Hemoglobin (Hb) Maintenance Period (weeks 21-36)&#xD;
&#xD;
        -  Follow-up Period (4 weeks)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 102 ESA-naïve subjects and 204 ESA-treated subjects will be enrolled and&#xD;
      randomized respectively in a 1:1 ratio to receive roxadustat at one of two starting doses as&#xD;
      below:&#xD;
&#xD;
        -  Low weight-based dosing: 70 mg TIW for body weight &lt; 60 kg or 100 mg TIW for body weight&#xD;
           ≥ 60 kg&#xD;
&#xD;
        -  Standard weight-based dosing: 100 mg TIW for body weight &lt; 60 kg or 120 mg TIW for body&#xD;
           weight ≥ 60 kg&#xD;
&#xD;
      After 20 weeks of treatment, all eligible subjects whose last two Hb levels ≥ 10.5 g/dL AND&#xD;
      change in Hb over most recent 4 weeks is &gt; - 10 g/dL will switch to receive roxadustat for&#xD;
      another 16 weeks to evaluate the efficacy and safety of new dosing regimens.&#xD;
&#xD;
      At end of Week 36, all subjects will discontinue roxadustat and enter a 4-week Follow-up&#xD;
      Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (Weeks 1-20): to descriptively compare efficacy of 2 starting doses</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>ESA-naïve: the proportion of subjects who achieve Hb ≥ 11.0 g/dL in the first 20 weeks&#xD;
ESA-treated: the proportion of subjects who achieve mean Hb ≥ 10.0 g/dL averaged over Week 17 visit to Week 21 visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Weeks 21-36): to compare efficacy of roxadustat at different frequencies</measure>
    <time_frame>Weeks 33-37</time_frame>
    <description>• Mean Hb averaged at Weeks 33-37 visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hb level from baseline to average over Weeks 17- 21 visits</measure>
    <time_frame>Weeks 17-21</time_frame>
    <description>Part 1 - Secondary analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESA-naïve: the proportion of subjects with mean Hb (averaged Week 17 to 21 visits) ≥ 10 g/dL</measure>
    <time_frame>Weeks 17-21</time_frame>
    <description>Part 1 - Secondary analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean Hb (averaged Weeks 33 to 37 visits) ≥ 10 g/dL</measure>
    <time_frame>Weeks 33-37</time_frame>
    <description>Part 2 - Secondary analyses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of dose adjustments during Part 1;</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>ESA-naïve: time to achieving Hb ≥ 10.5 g/dL</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>ESA-treated: the proportion of scheduled Hb values ≥ 10.0 g/dL</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>CKD Anemia in Dialysis Patients</condition>
  <arm_group>
    <arm_group_label>Part 1 (2 arms) and Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The purpose of Part 1 is to evaluate difference between low and standard weight-based doses and Part 2 is to evaluate the difference among dosing frequencies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1:&#xD;
Arm Type: Other&#xD;
Arm Title: Low weight-based dosing&#xD;
Arm 1: Low weight-based dosing&#xD;
Arm Description: Subjects in this arm will receive roxadustat 70 mg three times a week (TIW) for body weight &lt; 60 kg or 100 mg TIW for body weight ≥ 60 kg&#xD;
Arm Type: Other&#xD;
Arm Title: Standard weight-based dosing&#xD;
Arm 2: Standard weight-based dosing&#xD;
Arm Description: Subjects in this arm will receive roxadustat 100 mg TIW for body weight &lt; 60 kg or 120 mg TIW for body weight ≥ 60 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 2:&#xD;
Arm Type: Other&#xD;
Arm Title: Roxadustat&#xD;
Arm Description: Subjects in this arm will receive roxadustat at different dose frequencies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Roxadustat will be dosed orally</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 1 (2 arms) and Part 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Chronic kidney disease with end-stage renal disease (ESRD) on either hemodialysis (HD)&#xD;
        or peritoneal dialysis (PD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).&#xD;
&#xD;
          2. Cardiovascular risks such as: myocardial infarction, stroke, heart failure or a&#xD;
             thromboembolic event (e.g., deep venous thrombosis or pulmonary embolism) within 26&#xD;
             weeks prior to Day 1.&#xD;
&#xD;
          3. History of malignancy, myelodysplastic syndrome, and multiple myeloma.&#xD;
&#xD;
          4. Disease conditions that could impact red blood cell production.&#xD;
&#xD;
          5. Recent blood loss (i.e clinically significant gastrointestinal bleeding).&#xD;
&#xD;
          6. Women of childbearing potential and men with sexual partners of child bearing&#xD;
             potential who are not using adequate contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunrong Wang</last_name>
    <phone>+86 -21- 68810689</phone>
    <email>crwang@fibrogen.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Apple Zhao</last_name>
    <phone>+86 -21- 68810689</phone>
    <email>ggzhao@fibrogen.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Province</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia Autonomous Region</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110122</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease Dialysis</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>End stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

